相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。SARS-CoV-2 RBD protein enhances the oncolytic activity of the vesicular stomatitis virus
Almohanad A. Alkayyal et al.
FRONTIERS IN IMMUNOLOGY (2023)
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants
Ruediger Gross et al.
EBIOMEDICINE (2022)
A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges
Md. Mijanur Rahman et al.
VirusDisease (2022)
A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease
Stephanie L. Foster et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
A vesicular stomatitis virus-based prime-boost vaccination strategy induces potent and protective neutralizing antibodies against SARS-CoV-2 (vol 17, e1010092, 2021)
Gyoung Nyoun Kim et al.
PLOS PATHOGENS (2022)
Distinct VSV-based Nipah virus vaccines expressing either glycoprotein G or fusion protein F provide homologous and heterologous protection in a nonhuman primate model
Emmie de Wit et al.
EBioMedicine (2022)
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) and Spike (S) Proteins Antagonize Host Type I Interferon Response
Qi Zhang et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2021)
Magnetic Field-Assisted Laser Ablation of Titanium Dioxide Nanoparticles in Water for Anti-Bacterial Applications
Hasan H. Bahjat et al.
JOURNAL OF INORGANIC AND ORGANOMETALLIC POLYMERS AND MATERIALS (2021)
Pt(II)-Thiocarbohydrazone Complex as Cytotoxic Agent and Apoptosis Inducer in Caov-3 and HT-29 Cells through the P53 and Caspase-8 Pathways
Abeer A. Ibrahim et al.
PHARMACEUTICALS (2021)
Viral targets for vaccines against COVID-19
Lianpan Dai et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death
Robert W. Cross et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
M. Eugenia Dieterle et al.
CELL HOST & MICROBE (2020)
The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies
Lea Skak Filtenborg Frederiksen et al.
FRONTIERS IN IMMUNOLOGY (2020)
A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge
Yfat Yahalom-Ronen et al.
NATURE COMMUNICATIONS (2020)
SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development
Mei-Yue Wang et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2
Francesca Salamanna et al.
FRONTIERS IN MEDICINE (2020)
Dextran-coated superparamagnetic nanoparticles modified with folate for targeted drug delivery of camptothecin
Sharafaldin Al-Musawi et al.
ADVANCES IN NATURAL SCIENCES-NANOSCIENCE AND NANOTECHNOLOGY (2020)
Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens
Anahita Fathi et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Oncolytic viruses: a new class of immunotherapy drugs
Howard L. Kaufman et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses
David Safronetz et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Oncolytic vesicular stomatitis virus quantitatively and qualitatively improves primary CD8+ T-cell responses to anticancer vaccines
Byram W. Bridle et al.
ONCOIMMUNOLOGY (2013)
rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy
Lan Wu et al.
HUMAN GENE THERAPY (2008)